A Phase 1, Open-label Study of the Absorption, Metabolism, and Excretion of [14C]-LY3871801 in Healthy Male Participants
Latest Information Update: 09 Jan 2024
At a glance
- Drugs Ocadusertib (Primary)
- Indications Rheumatoid arthritis
- Focus Pharmacokinetics
- Sponsors Eli Lilly and Company
Most Recent Events
- 05 Jan 2024 Status changed from recruiting to completed.
- 10 Oct 2023 Status changed from not yet recruiting to recruiting.
- 26 Sep 2023 New trial record